Trizivir-Alone Arm Of NIH Trial Halted Due To Greater Effect In Sustiva Combos
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
First-line use of GlaxoSmithKline’s Trizivir is inferior to two treatment regimens containing Bristol-Myers Squibb’s Sustiva, according to interim results of a 1,147-patient NIH study of protease-inhibitor-sparing regimens for initial treatment of HIV.